Physician profile
Anthony A Flaim
NPI 1851687966
$11,497.05
in general payments reported to CMS, 2019-2025
42 companies · $2,930 in 2025
The $2,930 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $155 · 2021: $45.01 · 2022: $1,123 · 2023: $3,434 · 2024: $3,451 · 2025: $2,930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,770 · Education: $45.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,770.00 |
| Education | $45.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,965.25 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,699.74 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Harmony Biosciences LLC | $1,174.64 | 2022-2025 | Wakix |
| Regeneron Healthcare Solutions, INC. | $867.70 | 2022-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $548.07 | 2019-2025 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Mylan Specialty L.P. | $430.64 | 2022-2024 | Yupelri |
| Insmed, INC. | $424.99 | 2019-2024 | Arikayce |
| Jazz Pharmaceuticals INC. | $415.64 | 2023-2024 | Xywav |
| Genzyme Corporation | $391.86 | 2019-2024 | |
| Axsome Therapeutics, INC. | $370.59 | 2023-2025 | Sunosi |
| United Therapeutics Corporation | $298.02 | 2022-2024 | Tyvaso |
| Grifols USA, LLC | $288.54 | 2023-2025 | Prolastin-C Liquid, Xembify |
| Bayer Healthcare Pharmaceuticals INC. | $217.63 | 2023-2024 | |
| Ani Pharmaceuticals, INC. | $211.16 | 2023-2025 | Purified Cortrophin Gel |
| Electromed, INC. | $207.90 | 2024-2025 | Smartvest |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $185.53 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $182.30 | 2019-2024 | Xarelto |
| Viatris Specialty LLC | $169.07 | 2025 | Yupelri |
| Abbvie INC. | $148.76 | 2023-2024 | |
| Verona Pharma, INC. | $148.03 | 2025 | Ohtuvayre |
| Philips North America LLC | $132.85 | 2022-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Mallinckrodt Hospital Products INC. | $129.90 | 2022-2025 | Acthar |
| Inspire Medical Systems, INC. | $119.75 | 2024-2025 | Inspire |
| Merck Sharp & Dohme LLC | $98.04 | 2020-2025 | Zerbaxa |
| Allergan, INC. | $69.31 | 2019-2020 | |
| Pfizer INC. | $67.77 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $65.30 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $63.53 | 2023 | Eliquis, Camzyos |
| Inogen, INC. | $54.17 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Alexion Pharmaceuticals, INC. | $52.49 | 2022-2024 | Ultomiris |
| Lilly USA, LLC | $46.11 | 2024-2025 | Zepbound |
| Genentech USA, INC. | $37.13 | 2019 | |
| Aero US INC | $28.88 | 2025 | Aerogen Solo Nebulizer System, Aerogen Usb Controller System, Aerogen Solo; Aerogen Ultra |
| Sunovion Pharmaceuticals INC. | $28.43 | 2019 | |
| Vifor Pharma, INC. | $24.70 | 2025 | Zemaira |
| Resmed Corp | $24.08 | 2024 | |
| Tactile Systems Technology INC | $23.62 | 2024 | Flexitouch Plus, Entre Plus |
| Novartis Pharmaceuticals Corporation | $22.87 | 2020 | |
| Vapotherm INC | $19.16 | 2021 | |
| Amgen INC. | $16.27 | 2020 | |
| Paratek Pharmaceuticals, INC. | $15.06 | 2023 | Nuzyra |
| Avanir Pharmaceuticals, INC. | $11.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Flaim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.